Soleno Therapeutics
Soleno Therapeutics (SLNO) announced that’s Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets for the treatment of adults and children four years and older with Prader-Willi syndrome (PWS) who have hyperphagia had been validated by the European Medicines Agency (EMA).
From Soleno Therapeutics
“The validation . . .
This content is for paid subscribers.
Trick or Trade
June 5, 2025
